Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression
Inavolisib Plus Palbociclib/Fulvestrant Bolsters PFS in HR+/HER2–, PIK3CA-Mutant Breast Cancer
Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC
Dr Freedland on Treatment Suspension and HRQoL During the EMBARK Trial in nmHSPC
2 Commerce Drive
Cranbury, NJ 08512